Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A set of minimal quality criteria does exist for constitution of a clinical-grade iPSC-derived therapeutic throughout the pipeline”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [91]
In the citing paper
“while a framework exists for therapeutic generation through CGMP”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [91]
In the citing paper
“there are no standardized requirements for systems implemented and protocols used, leading to differing process effectiveness, robustness, and outcomes90,91.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
A ROCK inhibitor permits survival of dissociated human embryonic stem cells
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J. B., Nishikawa, S., Nishikawa, S.-I., Muguruma, K., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1310 · Cited by 2,055
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds.
Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., Zhao, T., Ye, J., Yang, W., Liu, K., et al. (2013) · Science · doi:10.1126/science.1239278 · Cited by 1,402
Modeling ALS with motor neurons derived from human induced pluripotent stem cells
Sances, S., Bruijn, L. I., Chandran, S., Eggan, K., Ho, R., Klim, J. R., Livesey, M. R., Lowry, E., Macklis, J. D., Rushton, D., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4273 · Cited by 289
Baghbaderani, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., Zeng, X., Warren, K., Kovarcik, D. P., Fellner, T., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.015 · Cited by 212
Self-citationEnd-to-End Platform for Human Pluripotent Stem Cell Manufacturing
Pandey, P. R., Tomney, A., Woon, M. T., Uth, N., Shafighi, F., Ngabo, I., Vallabhaneni, H., Levinson, Y., Abraham, E., & Friedrich Ben-Nun, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010089 · Cited by 42
Ahmadian Baghbaderani, B., Tian, X., Scotty Cadet, J., Shah, K., Walde, A., Tran, H., Kovarcik, D. P., Clarke, D., & Fellner, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161229 · Cited by 13
Research works printed but not linked: 34
- Rao M (2008) Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues. Gene Ther 15(2):82–88. https://doi.org/10.1038/sj.gt.3303061 · DOI
- Rao M, Condic ML (2008) Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. Stem Cells Dev 17(1):1–10. https://doi.org/10.1089/scd.2008.0013 · DOI
- Chen VC, Couture SM, Ye J, Lin Z, Hua G, Huang HI, Wu J, Hsu D, Carpenter MK, Couture LA (2012) Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res 8(3):388–402. https://doi.org/10.1016/j.scr.2012.02.001 · DOI
- Ellerstrom C, Strehl R, Moya K, Andersson K, Bergh C, Lundin K, Hyllner J, Semb H (2006) Derivation of a xeno-free human embryonic stem cell line. Stem Cells 24(10):2170–2176. https://doi.org/10.1634/stemcells.2006-0130 · DOI · Paper page
- Shinde V, Sureshkumar P, Sotiriadou I, Hescheler J, Sachinidis A (2016) Human embryonic and induced pluripotent stem cell based toxicity testing models: future applications in new drug discovery. Curr Med Chem 23(30):3495–3509 · DOI · Paper page
- Lee DF, Su J, Kim HS, Chang B, Papatsenko D, Zhao R, Yuan Y, Gingold J, Xia W, Darr H, Mirzayans R, Hung MC, Schaniel C, Lemischka IR (2015) Modeling familial cancer with induced pluripotent stem cells. Cell 161(2):240–254. https://doi.org/10.1016/j.cell.2015.02.045 · DOI · Paper page
- Ilic D, Devito L, Miere C, Codognotto S (2015) Human embryonic and induced pluripotent stem cells in clinical trials. Br Med Bull 116:19–27. https://doi.org/10.1093/bmb/ldv045 · DOI
- Guhr A, Kobold S, Seltmann S, Seiler Wulczyn AEM, Kurtz A, Loser P (2018) Recent trends in research with human pluripotent stem cells: impact of research and use of cell lines in experimental research and clinical trials. Stem Cell Reports 11(2):485–496. https://doi.org/10.1016/j.stemcr.2018.06.012 · DOI · Paper page
- Takahashi J (2017) Strategies for bringing stem cell-derived dopamine neurons to the clinic: the Kyoto trial. Prog Brain Res 230:213–226. https://doi.org/10.1016/bs.pbr.2016.11.004 · DOI
- Hu S, Yang J, Shangguan J, Eresen A, Li Y, Ma Q, Yaghmai V, Velichko Y, Hu C, Zhang Z (2019) Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a Kras(LSL-G12D) p53(LSL-R172H) Pdx1-Cre mouse model. Am J Cancer Res 9(8):1757–1765
- Shafa M, Yang F, Fellner T, Rao MS, Baghbaderani BA (2018) Human-induced pluripotent stem cells manufactured using a current good manufacturing practice-compliant process differentiate into clinically relevant cells from three germ layers. Front Med (Lausanne) 5:69. https://doi.org/10.3389/fmed.2018.00069 · DOI · Paper page
- Chou BK, Mali P, Huang X, Ye Z, Dowey SN, Resar LM, Zou C, Zhang YA, Tong J, Cheng L (2011) Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 21(3):518–529. https://doi.org/10.1038/cr.2011.12 · DOI · Paper page
- Shafa M, Panchalingam KM, Walsh T, Richardson T, Baghbaderani BA (2019) Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes. Biotechnol Bioeng 116(12):3228–3241. https://doi.org/10.1002/bit.27159 · DOI
- Baghbaderani BA, Syama A, Sivapatham R, Pei Y, Mukherjee O, Fellner T, Zeng X, Rao MS (2016) Detailed characterization of human induced pluripotent stem cells manufactured for therapeutic applications. Stem Cell Rev Rep 12(4):394–420. https://doi.org/10.1007/s12015-016-9662-8 · DOI · Paper page
- Shafa M, Walsh T, Panchalingam KM, Richardson T, Menendez L, Tian X, Suresh Babu S, Dadgar S, Beller J, Yang F, Baghbaderani BA (2019) Long-term stability and differentiation potential of cryopreserved cGMP-compliant human induced pluripotent stem cells. Int J Mol Sci 21(1). https://doi.org/10.3390/ijms21010108 · DOI
- Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467(7313):285–290. https://doi.org/10.1038/nature09342 · DOI · Paper page
- Rao M, Ahrlund-Richter L, Kaufman DS (2012) Concise review: cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells 30(1):55–60. https://doi.org/10.1002/stem.770 · DOI · Paper page
- Gonzalez M, Martin-Ruiz I, Jimenez S, Pirone L, Barrio R, Sutherland JD (2011) Generation of stable Drosophila cell lines using multicistronic vectors. Sci Rep 1:75. https://doi.org/10.1038/srep00075 · DOI · Paper page
- Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, Huangfu D, Akutsu H, Liu DR, Rubin LL, Eggan K (2009) A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 5(5):491–503. https://doi.org/10.1016/j.stem.2009.09.012 · DOI · Paper page
- Lyssiotis CA, Foreman RK, Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, Charette BD, Bouchez LC, Bollong M, Kunick C, Brinker A, Cho CY, Schultz PG, Jaenisch R (2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A 106(22):8912–8917. https://doi.org/10.1073/pnas.0903860106 · DOI · Paper page
- Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S (2009) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4(1):16–19. https://doi.org/10.1016/j.stem.2008.11.014 · DOI · Paper page
- Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26(7):795–797. https://doi.org/10.1038/nbt1418 · DOI · Paper page
- Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S (2011) A more efficient method to generate integration-free human iPS cells. Nat Methods 8(5):409–412. https://doi.org/10.1038/nmeth.1591 · DOI · Paper page
- Goh PA, Caxaria S, Casper C, Rosales C, Warner TT, Coffey PJ, Nathwani AC (2013) A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells. PLoS One 8(11):e81622. https://doi.org/10.1371/journal.pone.0081622 · DOI · Paper page
- Nie Y, Walsh P, Clarke DL, Rowley JA, Fellner T (2014) Scalable passaging of adherent human pluripotent stem cells. PLoS One 9(1):e88012. https://doi.org/10.1371/journal.pone.0088012 · DOI · Paper page
- Stacey GN, Crook JM, Hei D, Ludwig T (2013) Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells? Cell Stem Cell 13(4):385–388. https://doi.org/10.1016/j.stem.2013.09.007 · DOI
- ICH (2005) Q2 (R1), Validation of analytical procedures: text and methodology, ICH harmonised tripartite guideline. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, Chicago, USA
- Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ (2012) Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111(3):344–358. https://doi.org/10.1161/CIRCRESAHA.110.227512 · DOI · Paper page
- Krawetz R, Taiani JT, Liu S, Meng G, Li X, Kallos MS, Rancourt DE (2010) Large-scale expansion of pluripotent human embryonic stem cells in stirred-suspension bioreactors. Tissue Eng Part C Methods 16(4):573–582. https://doi.org/10.1089/ten.TEC.2009.0228 · DOI · Paper page
- Zweigerdt R, Olmer R, Singh H, Haverich A, Martin U (2011) Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc 6(5):689–700. https://doi.org/10.1038/nprot.2011.318 · DOI · Paper page
- Butler M (2003) Animal cell culture and technology. Taylor & Francis, London. https://doi.org/10.4324/9780203427835 · DOI
- Aunins JG, Woodson BA Jr, Hale TK, Wang DI (1989) Effects of paddle impeller geometry on power input and mass transfer in small-scale animal cell culture vessels. Biotechnol Bioeng 34(9):1127–1132. https://doi.org/10.1002/bit.260340902 · DOI
- Shuler ML, Kargi F (2002) Bioprocess engineering: basic concepts, 2nd edn. Prentice Hall PTR, Upper Saddle River
- Borys BS, Le A, Roberts EL, Dang T, Rohani L, Hsu CY, Wyma AA, Rancourt DE, Gates ID, Kallos MS (2019) Using computational fluid dynamics (CFD) modeling to understand murine embryonic stem cell aggregate size and pluripotency distributions in stirred suspension bioreactors. J Biotechnol 304:16–27. https://doi.org/10.1016/j.jbiotec.2019.08.002 · DOI
Cited by
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00183-7 · Cited by 33
Suresh Babu, S., Duvvuru, H., Baker, J., Switalski, S., Shafa, M., Panchalingam, K. M., Dadgar, S., Beller, J., & Ahmadian Baghbaderani, B. (2023) · Biotechnology Reports · doi:10.1016/j.btre.2023.e00784 · Cited by 22
“To properly address the manufacturing challenges for commercialization of iPSC-based therapies, we propose a few initiatives including focusing on detailed iPSC characterization [4], long-term stability of cGMP compliant iPSC [6], use of computer-controlled 3D bioreactor-based manufacturing process to reduce the labor…”
MethodSelf-citation
Metadata
- Authors
- Dashtban, M., Panchalingam, K. M., Shafa, M., & Ahmadian Baghbaderani, B.
- Venue
- Methods in Molecular Biology
- Publisher
- Springer US
- Published
- 2020
- Pages
- 179-198
- ISSN
- 1064-3745
- 1940-6029
- Cited by
- 17
- References
- 9
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.